期刊文献+

一个遗传性出血性毛细血管扩张症家系的临床和基因诊断

Clinical genetic analysis and diagnosis of a family with hereditary hemorrhagic telangiectasia
原文传递
导出
摘要 目的通过分析一个遗传性出血性毛细血管扩张症(hereditary hemorrhagic telangiectasia,HHT)家系的临床和基因诊断,探索临床及基因检测结合的方法对该病的诊断意义。方法收集先证者及其家系成员的病史资料,应用聚合酶链反应测序的方法对ENG、ACVRL1、SMAD4和GDF2基因编码区进行序列分析,结合临床特征及基因检测结果进行综合诊断。鉴定出致病性基因变异后,对家系中3代11名成员进行致病基因突变检测。结果先证者及其他9名家系成员中存在ACVRL1基因c.715_716delAG突变,引起p.S239C,第239位的半胱氨酸替换了丝氨酸,7例疑诊病例得到确诊,检测到2例无症状患者携带突变位点。结论临床特征和基因检测相结合的方法可确定HHT的病因并分类诊断,便于HHT的早期诊断及预防。 Objective To explore the diagnostic significance of the combination of clinical and genetic detection of hereditary hemorrhagic telangiectasia(HHT)by analyzing the clinical and genetic diagnosis of a family with HHT.Methods Medical history data of the probands and their family members were collected,and the sequence analyses of coding regions of ENG,ACVRL1,SMAD4 and GDF2 genes were performed by PCR-sequencing method,and a comprehensive diagnosis was made based on the clinical features and gene detection results.After the pathogenic gene variation was identified,11 members of 3 generations of the family were tested for pathogenic gene mutation.Results There was an ACVRL1 c.715_716delAG mutation in the proband and 9 other family members,which caused p.S239C.Based on the clinical and genetic findings,the 7 suspected were diagnosed and 2 asymptomatic patients were found to carry the mutation site.Conclusion The combination of clinical features and gene detection can determine the etiology and classification of HHT,which is convenient for the early diagnosis and prevention of the disease.
作者 宋晓宇 杨玉娟 姚尧 张宇 宋西成 Song Xiaoyu;Yang Yujuan;Yao Yao;Zhang Yu;Song Xicheng(Department of Otorhinolaryngology Head and Neck Surgery,Yuhuangding Hospital of Qingdao University,Yantai 264000,Shandong Province,China;Taishan Scholar Laboratory,Yuhuangding Hospital of Qingdao University,Yantai 264000,Shandong Province,China)
出处 《中华耳鼻咽喉头颈外科杂志》 CSCD 北大核心 2021年第12期1307-1312,共6页 Chinese Journal of Otorhinolaryngology Head and Neck Surgery
关键词 遗传性出血性毛细血管扩张症 基因突变 基因诊断 Hereditary hemorrhagic telangiectasia Genetic mutation Genetic diagnosis
  • 相关文献

参考文献4

二级参考文献73

  • 1Hoag .IB, Terry P, Mitchell S, Reh D, Merlo CA. An Epistaxis Severity Score for hereditary hemorrhagic telangiectasia. Laryngoscope 2010;120:838-43.
  • 2Kamezis TT, Davidson TM. Efficacy of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 2011;121:636-8.
  • 3Kamezis TT, Davidson TM. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy. Laryngoscope 2012;122:495-7.
  • 4Guldmann R, Dupret A, Nivoix Y, Schultz P, Debry C. Bevacizumab nasal spray: Noninvasive treatment of epistaxis in patients with Rendu-Osler disease. Laryngoscope 2012;122:953-5.
  • 5Chen CH, Hsu HH, Hu RH, Lee PH. Ho CM. Long-term therapy with thalidomide in hereditary hemorrhagic telangiectasia: Case report and literature review. J Clin Pharmacol 2012;52:1436-40.
  • 6Amanzada A, Toppler GJ, Cameron S. Schworer H, Ramadori G. A case report of a patient with hereditary hemorrhagic telangiectasia treated successively with thalidomide and bevacizumab. Case RepOncol 2010;3:463-70.
  • 7Lebrin F, Srun S, Raymond K, Martin S, van den Brink S, Freitas C, el al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 2010;16:420-8.
  • 8Shovlin CL, Guttmacher AE, Busearini E, Faughnan ME, Hyland RH. Westermann CJ, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000;91:66-7.
  • 9Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004;363:1802-11.
  • 10Pardali E, Goumans MJ, ten Dijke P. Signaling by members of the TGF-beta family in vascular morphogenesis and disease. Trends Cell Biol 2010;20:556-67.

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部